Literature DB >> 23336744

Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study.

N A Zakai1, P W Callas, A B Repp, M Cushman.   

Abstract

BACKGROUND: We sought to define the risk factors present at admission for venous thromboembolism (VTE) in medical inpatients and develop a risk model for clinical use.
METHODS: Between January 2002 and June 2009, 299 cases of hospital-acquired VTE were frequency matched to 601 controls. Records were abstracted using a standard form for characteristics of the thrombosis, medical conditions and other risk factors. Weighted logistic regression and survey methods were used to develop a risk model for hospital-acquired VTE that was validated by bootstrapping.
RESULTS: VTE complicated 4.6 per 1000 admissions. Two risk assessment models were developed, one using laboratory data available at admission (Model 1) and the other excluding laboratory data (Model 2). Model 1 consisted of the following risk factors (points): history of congestive heart failure (5), history of inflammatory disease (4), fracture in the past 3 months (3), history of VTE (2), history of cancer in the past 12 months (1), tachycardia (2), respiratory dysfunction (1), white cell count ≥ 11 × 10(9) /L (1), and platelet count ≥ 350 × 10(9) /L (1). Model 2 was similar, except respiratory dysfunction had 2 points and white cell and platelet counts were removed. The c-statistic for Model 1 was 0.73 (95% CI 0.70, 0.77) and for Model 2 0.71 (95% CI 0.68, 0.75).
CONCLUSIONS: We present a VTE risk assessment model for use in medical inpatients. The score is simple and relies on information known at the time of admission and typically collected in all medical inpatients. External validation is needed.
© 2013 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Year:  2013        PMID: 23336744     DOI: 10.1111/jth.12147

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  16 in total

Review 1.  Venous thrombosis and cancer: from mouse models to clinical trials.

Authors:  Y Hisada; J E Geddings; C Ay; N Mackman
Journal:  J Thromb Haemost       Date:  2015-06-26       Impact factor: 5.824

2.  Racial and regional differences in venous thromboembolism in the United States in 3 cohorts.

Authors:  Neil A Zakai; Leslie A McClure; Suzanne E Judd; Monika M Safford; Aaron R Folsom; Pamela L Lutsey; Mary Cushman
Journal:  Circulation       Date:  2014-02-07       Impact factor: 29.690

Review 3.  Defining quality indicators for best-practice management of inflammatory bowel disease in Canada.

Authors:  Geoffrey C Nguyen; Shane M Devlin; Waqqas Afif; Brian Bressler; Steven E Gruchy; Gilaad G Kaplan; Liliana Oliveira; Sophie Plamondon; Cynthia H Seow; Chadwick Williams; Karen Wong; Brian M Yan; Jennifer Jones
Journal:  Can J Gastroenterol Hepatol       Date:  2014-05

Review 4.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

5.  Inflammation markers and incident venous thromboembolism: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort.

Authors:  N C Olson; M Cushman; P L Lutsey; L A McClure; S Judd; R P Tracy; A R Folsom; N A Zakai
Journal:  J Thromb Haemost       Date:  2014-10-31       Impact factor: 5.824

6.  Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews.

Authors:  Andrea J Darzi; Allen B Repp; Frederick A Spencer; Rami Z Morsi; Rana Charide; Itziar Etxeandia-Ikobaltzeta; Kenneth A Bauer; Allison E Burnett; Mary Cushman; Francesco Dentali; Susan R Kahn; Suely M Rezende; Neil A Zakai; Arnav Agarwal; Samer G Karam; Tamara Lotfi; Wojtek Wiercioch; Reem Waziry; Alfonso Iorio; Elie A Akl; Holger J Schünemann
Journal:  Blood Adv       Date:  2020-10-13

7.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.

Authors:  Holger J Schünemann; Mary Cushman; Allison E Burnett; Susan R Kahn; Jan Beyer-Westendorf; Frederick A Spencer; Suely M Rezende; Neil A Zakai; Kenneth A Bauer; Francesco Dentali; Jill Lansing; Sara Balduzzi; Andrea Darzi; Gian Paolo Morgano; Ignacio Neumann; Robby Nieuwlaat; Juan J Yepes-Nuñez; Yuan Zhang; Wojtek Wiercioch
Journal:  Blood Adv       Date:  2018-11-27

8.  Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis.

Authors:  Andrea J Darzi; Samer G Karam; Rana Charide; Itziar Etxeandia-Ikobaltzeta; Mary Cushman; Michael K Gould; Lawrence Mbuagbaw; Frederick A Spencer; Alex C Spyropoulos; Michael B Streiff; Scott Woller; Neil A Zakai; Federico Germini; Marta Rigoni; Arnav Agarwal; Rami Z Morsi; Alfonso Iorio; Elie A Akl; Holger J Schünemann
Journal:  Blood       Date:  2020-05-14       Impact factor: 22.113

9.  Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment.

Authors:  Andrea J Darzi; Samer G Karam; Frederick A Spencer; Alex C Spyropoulos; Lawrence Mbuagbaw; Scott C Woller; Neil A Zakai; Michael B Streiff; Michael K Gould; Mary Cushman; Rana Charide; Itziar Etxeandia-Ikobaltzeta; Federico Germini; Marta Rigoni; Arnav Agarwal; Rami Z Morsi; Elie A Akl; Alfonso Iorio; Holger J Schünemann
Journal:  Blood Adv       Date:  2020-06-23

10.  Atrial fibrillation is related to lower incidence of deep venous thrombosis in patients with pulmonary embolism.

Authors:  Khalid Bin Waleed; Xumin Guan; Xintao Li; Yiheng Yang; Zhao Wang; Xiaomeng Yin; Zhengyan Wang; Jianghai Liu; Lianjun Gao; Dong Chang; Xianjie Xiao; Rongfeng Zhang; Gary Tse; Yunlong Xia
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.